Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedT-Cell Prolymphocyte LeukemiaSubgroupCD30+JAK2 rearrangementICD10C82.-C82.7C82.9C83.3C83.5C84.4C84.5C84.6C84.7C84.8C85.2C86.1C86.2C86.5C91.5-C91.6-C94.7-MeSHImmunoblastic LymphadenopathyLeukemia, Prolymphocytic, T-CellLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralSequenceSTUDY - levelChemotherapyChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineNo. Substances12345 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMesnaPegfilgrastimNo. Substances13467Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksAlopeciaAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityInfectionsNeuropathyNeutropeniaOral MucositisPyrexiaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDupuis JHeld GHorwitz SMoskowitz AJ Pfreundschuh MVan de Wyngaert ZDiseaseaggressives B-/T-NHL, Erstlinie, ECOG 0-3Peripheres T- oder NK-Zell Lymphom, kutanes T-Zell Lymphom (Stadium IB oder höher), T-PLLperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2rezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3T-Zell Lymphom rezidiviert oder therapierefraktär, ECOG 0-3OriginGroupe hospitalo-universitaire Chenevier Mondor, Creteil, France, ORACLE trialHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Memorial Sloan-Kettering Cancer Center, New York, NYMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupNHL-B1 trial, DSHNHLProtocols in Revision 9 protocols foundProtocols under revision.Azacitidine 300, T-cell Lymphoma (PID2688 V1.0)BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420 V1.0)CHOEP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID719 V1.0)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204 V1.0)Ruxolitinib 20, T-Cell Lymphoma / T-Cell Prolymphocyte Leukemia (PID2478 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)
